Showing results (11-20 of 4,249) with videos related to
Sort By:
Pageof 425
Current Clinical Pharmacology|April 8, 2011
Tissue protective and anti-fibrotic actions of suramin: new uses of an old drugNa Liu, Shougang ZhuangOncotarget|April 27, 2017
Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in ratsNa Liu, Liuqing Xu, Yingfeng Shi, et al.The Journal of Pathology|October 4, 2019
Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosisYingfeng Shi, Min Tao, Yi Wang, et al.Cell Death & Disease|June 20, 2020
Delayed treatment with an autophagy inhibitor 3-MA alleviates the progression of hyperuricemic nephropathyYingfeng Shi, Min Tao, Xiaoyan Ma, et al.Oncotarget|November 16, 2017
Targeting Src attenuates peritoneal fibrosis and inhibits the epithelial to mesenchymal transitionJun Wang, Li Wang, Liuqing Xu, et al.Journal of the American Society of Nephrology : JASN|December 19, 2015
Inhibition of EGF Receptor Blocks the Development and Progression of Peritoneal FibrosisLi Wang, Na Liu, Chongxiang Xiong, et al.BMJ Open|March 4, 2019
Relationship between serum uric acid and clustering of cardiovascular disease risk factors and renal disorders among Shanghai population: a multicentre and cross-sectional studyMin Tao, Xiaoling Pi, Xiaoyan Ma, et al.Frontiers in Pharmacology|September 9, 2021
Blockade of Autophagy Prevents the Development and Progression of Peritoneal FibrosisYingfeng Shi, Yan Hu, Yi Wang, et al.Frontiers in Immunology|August 1, 2022
Macrophages in Renal Injury, Repair, Fibrosis Following Acute Kidney Injury and Targeted TherapyHui Chen, Na Liu, Shougang ZhuangKidney International|January 18, 2013
Role of epidermal growth factor receptor in acute and chronic kidney injuryJinhua Tang, Na Liu, Shougang ZhuangPageof 425